Insider · CIK 0001487630
Julie Spellman Sweet
ceochairofficerdirector
Files at ACN (Accenture plc). First filing Oct 22, 2024, latest Feb 6, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $11M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ACN: Accenture plc
ACNOct 9, 2026 · close 209.06
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Side | Company | Value | Shares | Holdings change | Price context | Filed |
|---|---|---|---|---|---|---|---|
| 55Moderate | sell 610b5-1 | ACN Accenture plc | $3.5M | 8,793 | -43% | +20% from low · 0% from high | |
| 43Moderate | sell 810b5-1 | ACN Accenture plc | $885k | 2,497 | -8% | +6% from low · -6% from high | |
| 55Moderate | sell 910b5-1 | ACN Accenture plc | $2.9M | 8,136 | -40% | - | |
| 55Moderate | sell 910b5-1 | ACN Accenture plc | $3.4M | 9,000 | -31% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 5, 2026 | ACN Accenture plc | AGrant or award Class A ordinary shares | +205 | $189.10 | $39k | 16,999 | 33 d ago |
| Mar 5, 2025 | ACN Accenture plc | AGrant or award Class A ordinary shares | +112 | $346.13 | $39k | 12,116 | Mar 6, 2025 |
| Feb 14, 2025 | ACN Accenture plc | AGrant or award Class A ordinary shares | +80 | $0.00 | $0 | 12,036 | Feb 18, 2025 |
| Feb 14, 2025 | ACN Accenture plc | FTax withholding Class A ordinary shares | -32 | $389.22 | $12k | 12,004 | Feb 18, 2025 |
| Feb 5, 2025 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -324 | $390.96 | $127k | 20,327 | Feb 6, 2025 |
| Feb 5, 2025 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -1,274 | $392.34 | $500k | 19,053 | Feb 6, 2025 |
| Feb 5, 2025 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -1,652 | $393.21 | $650k | 17,401 | Feb 6, 2025 |
| Feb 5, 2025 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -691 | $394.29 | $272k | 16,710 | Feb 6, 2025 |
| Feb 5, 2025 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -3,796 | $395.57 | $1.5M | 12,914 | Feb 6, 2025 |
| Feb 5, 2025 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -1,056 | $396.24 | $418k | 11,858 | Feb 6, 2025 |
| Feb 5, 2025 | ACN Accenture plc | AGrant or award Class A ordinary shares10b5-1 | +98 | $394.38 | $39k | 11,956 | Feb 6, 2025 |
| Feb 1, 2025 | ACN Accenture plc | FTax withholding Class A ordinary shares | -8,215 | $383.32 | $3.1M | 20,651 | Feb 4, 2025 |
| Jan 17, 2025 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -1,402 | $354.10 | $496k | 29,961 | Jan 21, 2025 |
| Jan 17, 2025 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -1,017 | $354.91 | $361k | 28,944 | Jan 21, 2025 |
| Jan 17, 2025 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -78 | $355.84 | $28k | 28,866 | Jan 21, 2025 |
| Jan 5, 2025 | ACN Accenture plc | AGrant or award Class A ordinary shares | +110 | $351.96 | $39k | 31,305 | Jan 6, 2025 |
| Jan 5, 2025 | ACN Accenture plc | AGrant or award Class A ordinary shares | +1,533 | $0.00 | $0 | 32,838 | Jan 6, 2025 |
| Jan 5, 2025 | ACN Accenture plc | FTax withholding Class A ordinary shares | -1,475 | $351.96 | $519k | 31,363 | Jan 6, 2025 |
| Jan 1, 2025 | ACN Accenture plc | AGrant or award Class A ordinary shares | +17,008 | $0.00 | $0 | 31,195 | Jan 3, 2025 |
| Dec 5, 2024 | ACN Accenture plc | AGrant or award Class A ordinary shares | +1,790 | $356.90 | $639k | 14,187 | Dec 6, 2024 |
| Nov 15, 2024 | ACN Accenture plc | AGrant or award Class A ordinary shares | +166 | $0.00 | $0 | 12,465 | Nov 19, 2024 |
| Nov 15, 2024 | ACN Accenture plc | FTax withholding Class A ordinary shares | -68 | $354.38 | $24k | 12,397 | Nov 19, 2024 |
| Nov 5, 2024 | ACN Accenture plc | AGrant or award Class A ordinary shares | +111 | $344.81 | $38k | 12,299 | Nov 6, 2024 |
| Oct 28, 2024 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -4,094 | $361.12 | $1.5M | 16,230 | Oct 29, 2024 |
| Oct 28, 2024 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -1,826 | $361.99 | $661k | 14,404 | Oct 29, 2024 |
| Oct 28, 2024 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -1,084 | $363.15 | $394k | 13,320 | Oct 29, 2024 |
| Oct 28, 2024 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -434 | $363.85 | $158k | 12,886 | Oct 29, 2024 |
| Oct 28, 2024 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -425 | $364.33 | $155k | 12,461 | Oct 29, 2024 |
| Oct 28, 2024 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -273 | $366.13 | $100k | 12,188 | Oct 29, 2024 |
| Oct 21, 2024 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -2,149 | $375.23 | $806k | 27,175 | Oct 22, 2024 |
| Oct 21, 2024 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -6,156 | $376.39 | $2.3M | 21,019 | Oct 22, 2024 |
| Oct 21, 2024 | ACN Accenture plc | SOpen-market sale Class A ordinary shares10b5-1 | -695 | $377.04 | $262k | 20,324 | Oct 22, 2024 |
| Oct 15, 2024 | ACN Accenture plc | AGrant or award Class A ordinary shares | +33,146 | $0.00 | $0 | 45,334 | Oct 16, 2024 |
| Oct 15, 2024 | ACN Accenture plc | FTax withholding Class A ordinary shares | -16,010 | $368.22 | $5.9M | 29,324 | Oct 16, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.